Lyell Immunopharma Statistics Share Statistics Lyell Immunopharma has 19.21M
shares outstanding. The number of shares has increased by 0.34%
in one year.
Shares Outstanding 19.21M Shares Change (YoY) 0.34% Shares Change (QoQ) 0.32% Owned by Institutions (%) 2.58% Shares Floating 8.61M Failed to Deliver (FTD) Shares 789 FTD / Avg. Volume 0.87%
Short Selling Information The latest short interest is 132.97K, so 0.69% of the outstanding
shares have been sold short.
Short Interest 132.97K Short % of Shares Out 0.69% Short % of Float 0.85% Short Ratio (days to cover) 3.95
Valuation Ratios The PE ratio is -9.76 and the forward
PE ratio is -1.
Lyell Immunopharma's PEG ratio is
-0.24.
PE Ratio -9.76 Forward PE -1 PS Ratio 54867.93 Forward PS 12311.1 PB Ratio 8.74 P/FCF Ratio -20.55 PEG Ratio -0.24
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Lyell Immunopharma.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 7.06,
with a Debt / Equity ratio of 0.15.
Current Ratio 7.06 Quick Ratio 7.06 Debt / Equity 0.15 Debt / EBITDA -0.29 Debt / FCF -0.36 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $203.33 Profits Per Employee $-1.14M Employee Count 300 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -42.35% in the
last 52 weeks. The beta is -0.2, so Lyell Immunopharma's
price volatility has been lower than the market average.
Beta -0.2 52-Week Price Change -42.35% 50-Day Moving Average 10.71 200-Day Moving Average 11.55 Relative Strength Index (RSI) 72.24 Average Volume (20 Days) 90,616
Income Statement In the last 12 months, Lyell Immunopharma had revenue of 61K
and earned -342.99M
in profits. Earnings per share was -1.31.
Revenue 61K Gross Profit 61K Operating Income -358.75M Net Income -342.99M EBITDA -200.64M EBIT -220.27M Earnings Per Share (EPS) -1.31
Full Income Statement Balance Sheet The company has 105.6M in cash and 58.97M in
debt, giving a net cash position of 46.63M.
Cash & Cash Equivalents 105.6M Total Debt 58.97M Net Cash 46.63M Retained Earnings -1.35B Total Assets 385.45M Working Capital 245.31M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -162.39M
and capital expenditures -464K, giving a free cash flow of -162.86M.
Operating Cash Flow -162.39M Capital Expenditures -464K Free Cash Flow -162.86M FCF Per Share -0.62
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -588122.95% and -562285.25%.
Gross Margin 100% Operating Margin -588122.95% Pretax Margin -562285.25% Profit Margin -562285.25% EBITDA Margin -328922.95% EBIT Margin -588122.95% FCF Margin -266980.33%
Dividends & Yields LYEL does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for LYEL is $15,
which is 15.1% higher than the current price. The consensus rating is "Hold".
Price Target $15 Price Target Difference 15.1% Analyst Consensus Hold Analyst Count 2
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jun 2, 2025. It was a
backward
split with a ratio of 1:20.
Last Split Date Jun 2, 2025 Split Type backward Split Ratio 1:20
Scores Altman Z-Score -4.87 Piotroski F-Score 4
